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Use of reverse-transcriptase-based HIV-1 viral load
assessment to confirm low viral loads in newly
diagnosed patients in Switzerland
Beatrice N Vetter*, Cyril Shah, Jon B Huder, Jürg Böni and Jörg Schüpbach
Abstract
Background: Treatment-naïve patients newly diagnosed with HIV occasionally present with low viral RNA of ≤1’000
copies/ml, raising concerns about viral load underestimation. Because falsely low or undetectable viral loads might
lead to inadvertent virus transmission or treatment delays, confirmation of such cases by a sequence-independent
viral load test is recommended in Switzerland.
Methods: HIV-1 RNA ≤1’000 cp/ml by Roche’s or Abbott’s tests in patients newly diagnosed from 2010 to 2012 in
Switzerland were subjected to viral load testing by the product-enhanced-reverse transcriptase (PERT) assay. These
investigations were complemented with repeat and/or alternative viral RNA measurements.
Results: HIV-1 RNA ≤1’000 cp/ml was observed in 71 of 1814 newly diagnosed patients. The PERT assay suggested
clinically relevant viral load underestimation in 7 of 32 cases that could be investigated. In four patients, the PERT
viral load was 10-1’000-fold higher; this was confirmed by alternative HIV-1 RNA tests. Six of the 7 underestimates
had been obtained with meanwhile outdated versions of Roche’s HIV-1 RNA test. In the seventh patient, follow-up
revealed similar results for RNA and PERT based viral loads.
Conclusion: PERT assay revealed occasional severe viral load underestimation by versions of HIV-1 RNA tests
meanwhile outdated. Underestimation by contemporary tests appears rare, however.
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Background
The quantification of HIV-1 RNA in plasma has become
the standard for assessing a patient’s plasma viral load
(VL) at the time of diagnosis and throughout the course
of the disease. Real-time PCR-based nucleic acid tests
(NAT) have a high sensitivity and broad dynamic range
[1] and the use of fine-tuned primer/probe sets has
made it possible to detect isolates of HIV-1 groups M,
N, and O as well as all known subtypes and circulating
recombinant forms. However, due to the highly variable
nature of HIV, primer/probe binding to the target region
occasionally can be sub-optimal, resulting in underesti-
mation of VL [2,3]. It is important to establish such
underestimation at the time of diagnosis, as VL monitor-
ing will be used for monitoring disease progression and
the success of antiretroviral therapy (ART). Falsely low
or even undetectable viral load due to underestimation
may impact the interpretation of the success of ART and
increase the risk of inadvertent virus transmission. In
Switzerland, regulations on HIV confirmation testing
issued by the Swiss Federal Office of Public Health
(SFOPH) in 2006 therefore request that a VL ≤1’000 cp/ml
be confirmed by the product-enhanced reverse tran-
scriptase (PERT) assay, a sequence-independent test that
quantifies retrovirus particles based on their content of
enzymatically active reverse transcriptase (RT) [4]. This
test has been available in our country since 1994, and its
sensitivity is comparable to NAT [5,6]. VL based on the
PERT assay, or on other RT-based tests, have been shown
to correlate well with RNA-based VL over a wide dynamic
range (102-106 cp/ml) [6-8].
Here, we analyzed the frequency of NAT-based
VL ≤1’000 cp/ml among newly diagnosed, untreated
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HIV-1 patients in Switzerland and investigated whether
such low VL were true or due to underestimation. To
this end, we compared viral loads derived from NAT
and PERT at the time of diagnosis and complemented
these data with repeat and/or alternative NAT measure-
ments. Alternative NAT involved testing in a different
primer/probe target region, addressing the possibility of
sequence polymorphism-associated failure of viral RNA
detection.
Methods
Study population and organisation
The study included all patients newly diagnosed with
HIV-1 infection as notified to the SFOPH during 01/
2010-12/2012. NAT VL tests were performed at the time
of HIV diagnosis in one of 11 Swiss HIV notification la-
boratories commissioned by the SFOPH, or at the Swiss
National Center for Retroviruses (SNCR), commissioned
by the SFOPH to serve as the national HIV reference la-
boratory. All laboratories are accredited by the govern-
mental Swiss Accreditation Service (SAS) (http://www.
seco.admin.ch/sas/index.html?lang=en).
PERT assays in patients that had exhibited ≤1’000 cp/ml
of HIV-1 RNA were performed at the SNCR upon request
by a patient’s treating physician. In most instances, a new
blood sample was used for testing. If NAT and PERT VL
were determined in two separate samples, collection dates
for these samples had to be ≤100 days apart to minimize a
potential decrease in VL due to initiation of ART. All re-
peat and alternative NAT measurements were performed
on the second sample stored at the SNCR. Plasma samples
were stored at −80°C and thawed once for alternative
NAT and a second time for repeat NAT assessment. Mea-
surements were performed on undiluted samples or at a
maximal dilution of 1:4 in PBS.
RNA viral load tests
Laboratories performing the initial, diagnostic NAT
employed one of the following CE-marked tests: Roche
COBAS AmpliPrep/COBAS TaqMan HIV-1 test v1.0
(CTM1.0), Roche COBAS AmpliPrep/COBAS TaqMan
HIV-1 test v2.0 (CTM2.0), Roche COBAS Amplicor
HIV-1 Monitor v1.5 (CAM1.5) or Abbott RealTime
HIV-1 m2000 (ARm2000). The SNCR used CTM2.0 and
ARm2000 for repeat or alternative NAT. Repeat testing
with CTM1.0 and CAM1.5 was not possible, as these tests
were no longer available. If possible, these samples were
tested with both alternative NAT platforms (CTM2.0 and
ARm2000).
Product-enhanced-reverse-transcriptase assay
The PERT assay is an SAS-accredited method and was
performed as described previously [7]. cDNA amplifica-
tion and quantification was performed on the ABI7900
Sequence Detector (Perkin Elmer Biosystems, Norwalk,
CT, U.S.A.). Median cycle threshold (Ct)-values were
converted into RNA cp/ml based on a conversion curve
generated from plasma samples of 30 untreated, HIV-1
infected patients (Figure 1). NAT VL was assessed on
CTM2.0 during routine testing. The PERT assay and
confirmatory NAT testing on the ARm2000 platform
were performed on archived samples. The lower limit of
quantification for the PERT assay was at a Ct-value of
30, which corresponds to an HIV-1 RNA concentration
of 78 cp/ml.
Duration of infection and HIV-1 subtypes
The estimated duration of HIV infection was determined
by the patient’s antibody pattern in a confirmatory line
immunoassay (Inno-Lia™ HIV I/II Score) [9,10]. Classi-
fication into “recent” or “older” refers to an estimated
duration of infection of less or more than 120 days.
HIV-1 subtype information was obtained from the Swiss
drug resistance database.
Ethics
All data in this study were derived from diagnostic data
contained in anonymised mandatory HIV notifications
to the SFOPH. No informed consent was required for
the anonymised notifications.
Figure 1 Correlation of NAT- and PERT-derived viral loads. NAT
(CTM2.0) and PERT viral loads were determined on plasma samples
of 30 untreated HIV-1 infected individuals. The top x-axis shows the
PERT Ct-values used for the conversion to RNA log10 cp/ml. Dotted
lines indicate the 95% confidence interval of the regression curve.
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Results
Frequency and magnitude of low viral loads
During 01/2010-12/2012, the SFOPH registered 1814
patients newly diagnosed with HIV; approximately 0.5%
of these were infected by HIV-2 [11]. Seventy-one (3.9%)
of the HIV-1 infected patients had an initial, diagnostic
NAT VL ≤1’000 cp/ml in the absence of ART. Twelve
of these (0.7% of the total) had an undetectable VL. A
PERT assay was performed for 32 of the 71 patients, and
the low NAT VL ≤1’000 cp/ml was confirmed in 23
patients (72% of the 32) (Table 1 and Figure 2A). The
remaining 9 patients had a PERT VL >1’000 cp/ml, with
Table 1 Summary of NAT and PERT viral load results
Patient
ID
NAT cp/ml PERT cp/ml Subtype Δ days samples Recency Year
Diagnosis Repeat Alternative Diagnosis
CTM1.0 CTM1.0 CTM2.0 ARm2000
1 TND N/A 295 B 7 Older 2010
2 46 N/A 45‘282 46‘885 88‘733 CRF01_AE 10 Older 2010
3 70 N/A TND 4 Older 2010
4 257 N/A 7‘728 16‘635 11‘191 B 8 Older 2010
5 508 N/A 6‘254 8‘934 8‘428 CRF02_AG 15 Older 2011
CTM2.0 CTM2.0 ARm2000
6 TND TND TND 4 Older 2012
7 TND TND 14 Recent 2010
8 22 TND 19 Older 2012
9 38 TND TND 35 Older 2012
10 47 66 54 TND 23 Older 2012
11 53 TND 9 Older 2012
12 110 TND D 56 Older 2011
13 128 50 TND C 24 Older 2012
14 158 459 309 22 Older 2010
15 165 220 104 10 Older 2010
16 174 148 79 20 Recent 2010
17 210 258 195 CRF02_AG 69 Older 2012
18 299 618 574 B 23 Older 2010
19 447 62 296 308 24 Older 2011
20 480 296 209 82 CRF01_AE 12 Older 2012
21 551 1‘584 CRF02_AG 20 Older 2012
22 638 5‘303 B 0 Older 2011
23 936 2‘761 1‘565 0 Older 2010
24 990 157 CRF02_AG 21 Older 2012
ARm2000 ARm2000 CTM2.0
25 TND TND TND TND 77 Older 2012
26 TND 20 TND 28 Recent 2012
27 51 248 34 Recent 2010
28 302 403 B 95 Older 2010
CAM1.5 CAM1.5
29 182 N/A 605 3 Older 2011
30 224 N/A 19‘510 CRF02_AG 0 Older 2010
31 255 N/A 1‘642 G 21 Older 2010
32 427 N/A 2‘875 C 0 Older 2010
TND = target not detected; N/A = not applicable; Δ days = days between collection of first and second sample.
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seven patients (22%) exhibiting a PERT VL ≥3-fold
higher than the NAT VL (patient ID 2, 4, 5, 22, 30–32
in Table 1, Figure 2B). A ≥3-fold difference in VL is con-
sidered clinically significant according to NIH guidelines
[12]. In four of these patients, the VL differed by as
much as 10-1’000 fold (patient ID 2, 4, 5, 30), suggesting
a severe VL underestimation by the respective NAT. For
all but one (patient ID 22) of the seven patients, NAT
VL had been determined either with CTM1.0 (patient
ID 2, 4, 5) or CAM1.5 (patient ID 30–32), i.e. with tests
for which VL underestimation has been reported previ-
ously [2,13-16]. Plasma for alternative NAT assessment
was available for three patients assessed using CTM1.0,
and testing with the successor CTM2.0 as well as with
the ARm2000 platform both confirmed a VL >1’000 cp/
ml, supporting the PERT assay results (Table 1). Conse-
quently, the ratio of PERT to NAT VL decreased
to <3-fold for these patients (Figure 2B).
Due to the lack of sample, we could not conduct
repeat or alternative NAT-measurement for the four
remaining patients with ≥3-fold underestimation (patient
ID 22, 30–32). However, comparison of NAT (CTM2.0
and m2000) and PERT VL in routine follow-up samples
of two of these patients (patient ID 22 and 31) did not
show a persistent difference in VL. Average fold differ-
ence of PERT to CTM2.0 and m2000 were 1.8 (±2.3)
and 2.9 (±4.0) for patient ID 22 (n = 7), and 5.5 and 3.0
for patient ID 31 (n = 2). This suggests technical variabil-
ity or laboratory error as possible reasons for the appar-
ent initial underestimation in these cases.
Alternative NAT measurements for all other patients
(14 samples available) confirmed the low diagnostic
NAT VL ≤1’000 cp/ml, indicating a genuine low VL at
the time of diagnosis.
Discussion
In this study we investigated whether commercial viral
load assays in use during the past few years provided reli-
able concentrations of HIV-1 RNA in plasma. We focused
our analysis on patients with ≤1’000 cp/ml, because the
possible risks for untoward consequences of VL underesti-
mation, namely a delay of ART or further virus transmis-
sion in a false belief of being non-infectious [17,18], are
highest in this group. Confirmatory testing of the VL was
possible in only 32 of the 71 patients with an initial NAT
VL ≤1’000 cp/ml (45%). Possible reasons for this low rate
may include the following: Usually, a new blood sample
was needed for a PERT assay at the SNCR, which required
the patient returning to the physician who received the in-
formation that a PERT assay was considered necessary. If
the initial physician had meanwhile transferred the patient
to an HIV specialist, this information may not have been
forwarded to the specialist. Moreover, the decision of
whether a test is performed or not ultimately remains in
the physician’s responsibility; conceivable reasons for not
performing a PERT assay include transient stay in the
country or costs. Finally, it may not always have been pos-
sible to link a PERT result obtained for a patient sample
received under full personal identity, with the coded per-
sonal information in the HIV notification.
Aside from these limitations, our analysis showed that
the PERT assay confirmed the low diagnostic NAT VL
in 78% of patients who had both tests. Seven patients
had a clinically significant higher VL by PERT than
NAT, with four patients showing a >10-fold difference.
In three of these four patients we confirmed technical
underestimation as the reason for the diagnostic low
RNA VL, as demonstrated by significantly higher VL
measurements when using alternative NAT platforms.
Figure 2 Comparison of NAT and PERT viral loads. A. Viral load measured by NAT and PERT at the time of diagnosis. PERT-derived viral loads
were calculated based on the conversion shown in Figure 1. Samples below the limit of detection (LOD) were set to the LOD values as marked
by the dotted lines. B. Ratio of PERT to NAT viral loads in the quantifiable range for PERT viral loads at the time of diagnosis and NAT viral loads
measured at the time of diagnosis, during repeat testing and/or alternative (alt) testing with CTM2.0 or ARm2000. The area between dotted lines
indicates changes in VL <3-fold. Symbols: ○ CTM1.0, ● CTM2.0, ♦ ARm2000, ■ CAM1.5, Δ PERT.
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These four most discrepant cases had all been tested
with earlier NAT versions now outdated. Indeed, under-
estimation has been observed repeatedly for both
CAM1.5 [13,15] and CTM1.0 [2,14,16] in the past. One
patient showed a ≥3-fold NAT-VL underestimation on
the CTM2.0 compared to PERT, which disappeared in
later samples. In this case we cannot exclude some tech-
nical variance of the PERT assay.
The majority of patients were classified as having an
older infection, thus minimizing concerns about large
changes in VL between the first and second sample col-
lected. Four patients classified as having a recent infec-
tion (patient ID 7, 16, 26, 27), and all had a NAT and
PERT VL of ≤1’000 cp/ml. As such low VL are rarely
seen in patients with recent HIV-1 infection, we cannot
exclude the possibility that the diagnostic NAT VL was
falsely low, but nevertheless “confirmed” by PERT be-
cause the second sample was no longer in the acute, but
in the chronic phase of infection in which the VL was
already at the lower set-point. We can also not exclude
the possibility that the classification as recent infection
was false, because the diagnostic specificity of the algo-
rithm used in these four cases was only 93% [9]. There-
fore, it is impossible to draw any safe conclusion regarding
the true VL at the time of diagnosis in these four cases.
Both B and non-B subtypes were affected by NAT-based
VL underestimation in our study, in agreement with others
who found that underestimation was associated with a rare
polymorphism in the viral genome [19]. With the intro-
duction of CTM2.0, which uses dual target detection in
gag and LTR, VL underestimation decreased dramatically
[16,20,21]. The ARm2000 platform uses the IN region as
target, and VL measurements performed by CTM2.0 and
ARm2000 were found to correlate well [15]. Despite all
technological improvement, VL underestimation may still
occasionally occur even with the contemporary NAT gen-
eration [22]. This could also be the reason that one of the
patients shown in Figure 1 has a PERT VL well outside
the lower limit of the 95% confidence interval.
In our study population, severe NAT VL underestima-
tion was restricted to patients for whom the initial diag-
nostic VL measurement was performed on NAT platforms
outdated today. Although we did not find similar severe
VL underestimation for any of the 23 patients assessed on
either CTM2.0 or m2000, the upper limit of the 95% con-
fidence interval of this zero frequency is at 12.2%, suggest-
ing a certain possibility for underestimation even with
contemporary viral load tests. Continuation of the rule to
confirm low VL with an alternative test is thus justified
from a statistical viewpoint.
Conclusion
In light of the rapidly evolving global HIV-1 quasispecies
it is virtually unavoidable that variants will arise which
will be detected sub-optimally by a given sequence-
based VL test. Confirmation of low VL by alternative
methods like the sequence-independent PERT assay or a
NAT targeting a different region of the viral genome will
help to minimise such cases.
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